Все публикации

0:35:15

JAK Inhibition for the Treatment of Vitiligo

0:32:26

Exploring the Latest Updates in the Epidermolysis Bullosa Treatment Landscape

0:56:34

Achieving More: How and When to Switch Systemic Therapies in Atopic Dermatitis?

0:33:42

IL 31 Mechanism of Action and Clinical Implications for Prurigo Nodularis

0:32:15

Exposing the Epidermolysis Bullosa Patient Burden and Challenges in Disease Management

0:47:38

Chronic Hand Eczema: All Hands on Deck

0:48:34

Examining the Gaps and Challenges in Diagnosing and Treating Prurigo Nodularis - Episode 1

0:59:50

Skirting Steroids in Atopic Dermatitis: New Therapies and Expert Strategies for Long-term Control

0:57:34

Choosing the Right Path: JAK Inhibitors or Biologics for Atopic Dermatitis?

0:43:47

Skirting Steroids in Atopic Dermatitis (Part 1)

0:57:52

Setting the Stage: Effective Onboarding of your AD Patients onto JAK Inhibitor Therapy

0:50:52

The Quest for Itch Free, Clear Skin in Atopic Dermatitis New Practice Informing Evidence

0:05:20

Alopecia Areata in Adolescence Patient Perspective | Laura Mathias

0:38:19

Hidradenitis Suppurativa: Defining Window of Opportunity for Moderate-to-Severe Patients

0:47:15

JAK Inhibitors in Action: Effectiveness in Atopic Dermatitis

0:02:56

Tapinarof for Atopic Dermatitis - Mechanism of Action

0:30:27

Psoriasis in Skin of Color Unplugged: Patient and Disease Advocacy

0:38:29

Psoriasis in Skin of Color Unplugged: Advancing Diversity and Inclusion in Clinical Trials

0:26:42

Psoriasis in Skin of Color Unplugged: Gaps in Diagnosis and Dermatologist Training

0:23:41

Psoriasis in Skin | Disparities and Access to Care

0:48:51

The Spectrum of Atopic Dermatitis and the Emerging Role of JAK Inhibitors - E1

0:02:01

Clascoterone Mechanism of Action

0:02:52

Tapinarof for Plaque Psoriasis - Mechanism of Action

0:12:58

Christopher Bunick, MD - Update on Contamination in Skincare Products: Benzene Returns to the News